zoledronic acid




Concise Prescribing Info
Zoledronic acid
Hypercalcemia of malignancy (HCM), multiple myeloma, bone metastases from solid tumors (including prostate cancer, breast cancer, lung cancer, renal cell carcinoma, other solid tumors) in combination w/ standard antineoplastic therapy to prevent or delay potential complications from bone lesions.
Dosage/Direction for Use
IV infusion Hypercalcemia of malignancy [albumin-corrected serum Ca >12 mg/dL (3 mmol/L)] 4 mg as single dose over not <15 min following standard rehydration procedures. Bone metastases of solid tumors & osteolytic lesions of multiple myeloma (for patient w/ CrCl >60 mL/min) 4 mg as single dose over not <15 min every 3-4 wk. Patients w/ CrCl 50-60 mL/min 3.5 mg given every 3-4 wk. 40-49 mL/min 3.3 mg given every 3-4 wk. 30-39 mL/min 3 mg given every 3-4 wk.
Hypersensitivity. Pregnancy & lactation.
Special Precautions
Monitor serum levels of Ca, phosphate & Mg after initiating therapy. Evaluate serum creatinine conc prior to therapy. Hydration & electrolyte monitoring. Renal impairment; musculoskeletal pain; osteonecrosis of the jaw; atypical fractures of the femur; asthma. Discontinue use if ocular disturbances occur. May impair ability to drive or operate machinery. Hepatic impairment. Childn 1-17 yr. Elderly.
Adverse Reactions
Fever & flu-like syndrome, fatigue, chills, rigors, malaise & flushing, progression of cancer, weakness, rigors; CV, CNS, GI, hemic & lymphatic system effects; infections, inj site reactions, laboratory abnormalities,musculoskeletal/connective tissue & bone disorders; ocular, renal & urinary, resp, skin & SC tissue disorders.
Drug Interactions
Increased risk of hypocalcemia w/ loop diuretics. Possible additive effect in lowering serum Ca conc for prolonged periods w/ aminoglycosides. Increased risk of renal impairment w/ nephrotoxic drug (eg, other antineoplastic agents, ASA, NSAIDs) or drugs that significantly impact renal function (eg diuretics, ACE inhibitors). Increased risk of renal insufficiency w/ thalidomide (especially in patients w/ multiple myeloma).
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Osteomet concentrated soln for infusion 4 mg/5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in